Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03626636 · ClinicalTrials.gov registry record · Phase 2
A Clinical Trial Designed To Evaluate The Safety And Exploratory Efficacy Of 1.0 Mg Luminate® (Alg-1001) As A Treatment For Non-Exudative Macular Degeneration
A Phase 2 study, sponsored by Allegro Ophthalmics.
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
NCT03626636 is a Phase 2 study that has completed, run by Allegro Ophthalmics. The registered enrollment target is 42 participants.
The verdict
NCT03626636, a Phase 2 study, has completed, sponsored by Allegro Ophthalmics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
Study Summary
To evaluate the safety and exploratory efficacy of 1.0mg of Luminate® in patients with Intermediate Non-Exudative Macular Degeneration
Interventions
- OTHER Sham
- DRUG Risuteganib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2017-08-01 |
| Est. Completion | 2019-04-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03626636
The ClinicalTrials.gov registry entry for NCT03626636 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allegro Ophthalmics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sham is the first listed.
NCT03626636 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03626636 about?
NCT03626636 is a clinical study titled "A Clinical Trial Designed To Evaluate The Safety And Exploratory Efficacy Of 1.0 Mg Luminate® (Alg-1001) As A Treatment For Non-Exudative Macular Degeneration". To evaluate the safety and exploratory efficacy of 1.0mg of Luminate® in patients with Intermediate Non-Exudative Macular Degeneration
What is the current status of trial NCT03626636?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2017-08-01. Estimated completion is 2019-04-04.
What interventions are being tested in trial NCT03626636?
The interventions under investigation include: Sham (OTHER), Risuteganib (DRUG).
Who is sponsoring clinical trial NCT03626636?
This trial is sponsored by Allegro Ophthalmics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.